USFDA issues 2 observations for Alkem Labs St Louis facility

Published On 2022-09-17 05:00 GMT   |   Update On 2022-09-17 05:01 GMT

Maharashtra: Alkem Labs has recently announced that the US Food and Drug Administration (USFDA) has issued two observations after a pre-approval inspection at the Company's manufacturing facility located at St. Louis, USA.The inspection was conducted from 06th September 2022 to 14th September 2022. "At the end of the inspection, the Company has received Form 483 with two (2) observations....

Login or Register to read the full article

Maharashtra: Alkem Labs has recently announced that the US Food and Drug Administration (USFDA) has issued two observations after a pre-approval inspection at the Company's manufacturing facility located at St. Louis, USA.

The inspection was conducted from 06th September 2022 to 14th September 2022.
"At the end of the inspection, the Company has received Form 483 with two (2) observations. There is no data integrity observation," the company stated in a recent BSE filing.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

"This Pre-Approval Inspection is part of the routine business operations and the Company shall submit to USFDA within the stipulated timeline, a detailed response to close out the said observations," Alkem added.
Medical Dialogues team had earlier reported that the US Food and Drug Administration (USFDA) had issued Form 483 with 3 observations after an inspection at the Company's St. Louis manufacturing facility.

Alkem Labs is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company was founded by Samprada Singh in 1973. The company's portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O.

Akem has 20 manufacturing facilities at multiple locations in India and the United States of America.

Read also: Alkem Labs gets 1 observation from USFDA for Indore facility

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News